Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on March 30, 2005
J Am Soc Nephrol 16: 1320-1325, 2005
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2004100878

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2004100878v1
16/5/1320    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ribstein, J.
Right arrow Articles by Mimran, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribstein, J.
Right arrow Articles by Mimran, A.

Hemodynamics and Vascular Regulation

Relative Glomerular Hyperfiltration in Primary Aldosteronism

Jean Ribstein, Guilhem Du Cailar, Pierre Fesler and Albert Mimran

Department of Medicine, Hôpital Lapeyronie, Montpellier, France

Address correspondence to: Dr. Jean Ribstein, Department of Medicine, Hôpital Lapeyronie, 34295 Montpellier cedex 5, France. Phone: +33-467338443; Fax: +33-467338453; j-ribstein{at}chu-montpellier.fr

Received for publication October 22, 2004. Accepted for publication February 21, 2005.

Experimental and clinical data suggest that primary aldosteronism (PA) may be associated with cardiovascular hypertrophy and fibrosis, in part independent of the BP level. Whether PA may also result in specific deleterious effects on the kidneys was less studied. In 25 patients with tumoral PA, renal studies (urinary excretion of proteins, GFR, and effective renal plasma flow [ERPF], as clearances of technetium-labeled diethylene triaminopentaacetic acid and 131I-ortho iodohippurate, respectively) were performed both before and 6 mo after surgical cure. A control group consisting of patients with essential hypertension (EH) was studied before and after 6 mo of antihypertensive therapy. At baseline, PA and EH patients were similar with respect to demographic data, duration and level of hypertension, and GFR and ERPF. Urinary excretion of albumin and {beta}2 microglobulin were higher in PA than EH (88 ± 26 versus 39 ± 12 and 0.91 ± 0.23 versus 0.26 ± 0.19 mg/24 h, respectively; both P < 0.05). Adrenalectomy was followed by a decrease in arterial BP (by 28 ± 3/13 ± 2 mmHg), urinary excretion of albumin and {beta}2 microglobulin (by 48 ± 19 and 0.53 ± 0.21 mg/24 h, respectively), and GFR and ERPF (by 15 ± 3 and 54 ± 15 ml/min per 1.73 m2, respectively). In EH, a similar decrease in pressure was associated with a decrease in albuminuria but no change in GFR or ERPF. In 17 of the 25 PA patients who received a 6-mo treatment of spironolactone, both GFR and ERPF decreased in parallel with BP, similar to what was observed after surgery. These data suggest that PA was associated with relative hyperfiltration, unmasked after suppression of aldosterone excess.




This article has been cited by other articles:


Home page
HypertensionHome page
E. Pimenta, K. K. Gaddam, M. N. Pratt-Ubunama, M. K. Nishizaka, I. Aban, S. Oparil, and D. A. Calhoun
Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension
Hypertension, February 1, 2008; 51(2): 339 - 344.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
C. Catena, G. Colussi, E. Nadalini, A. Chiuch, S. Baroselli, R. Lapenna, and L. A. Sechi
Relationships of Plasma Renin Levels with Renal Function in Patients with Primary Aldosteronism
Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 722 - 731.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
H. Otani, F. Otsuka, K. Inagaki, M. Takeda, T. Miyoshi, J. Suzuki, T. Mukai, T. Ogura, and H. Makino
Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation
Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1513 - F1525.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. J. Wang, P. Gona, M. G. Larson, D. Levy, E. J. Benjamin, G. H. Tofler, P. F. Jacques, J. B. Meigs, N. Rifai, J. Selhub, et al.
Multiple Biomarkers and the Risk of Incident Hypertension
Hypertension, March 1, 2007; 49(3): 432 - 438.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Shibata, M. Nagase, S. Yoshida, H. Kawachi, and T. Fujita
Podocyte as the Target for Aldosterone: Roles of Oxidative Stress and Sgk1
Hypertension, February 1, 2007; 49(2): 355 - 364.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. Nagase, S. Yoshida, S. Shibata, T. Nagase, T. Gotoda, K. Ando, and T. Fujita
Enhanced Aldosterone Signaling in the Early Nephropathy of Rats with Metabolic Syndrome: Possible Contribution of Fat-Derived Factors
J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3438 - 3446.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Catena, G. Colussi, and L. A. Sechi
Renal Function in Primary Aldosteronism
Hypertension, December 1, 2006; 48(6): e110 - e110.
[Full Text] [PDF]


Home page
HypertensionHome page
G. P. Rossi, F. Mantero, A. C. Pessina, and For the PAPY Study Investigators
Response to Renal Function in Primary Aldosteronism: Is Glomerular Hyperfiltration a Hallmark of Primary Aldosteronism? Further Results from the Primary Aldosteronism Prevalence in Hypertension (PAPY) Study
Hypertension, December 1, 2006; 48(6): e111 - e112.
[Full Text] [PDF]


Home page
HypertensionHome page
G. P. Rossi, G. Bernini, G. Desideri, B. Fabris, C. Ferri, G. Giacchetti, C. Letizia, M. Maccario, M. Mannelli, M.-J. Matterello, et al.
Renal Damage in Primary Aldosteronism: Results of the PAPY Study
Hypertension, August 1, 2006; 48(2): 232 - 238.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
L. A. Sechi, M. Novello, R. Lapenna, S. Baroselli, E. Nadalini, G. L. Colussi, and C. Catena
Long-term renal outcomes in patients with primary aldosteronism.
JAMA, June 14, 2006; 295(22): 2638 - 2645.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP